Top

Published in:

Open Access 01-04-2007 | Oncology

Imaging oxygenation of human tumours

Authors: Anwar R. Padhani, Kenneth A. Krohn, Jason S. Lewis, Markus Alber

Published in: European Radiology | Issue 4/2007

Abstract

Tumour hypoxia represents a significant challenge to the curability of human tumours leading to treatment resistance and enhanced tumour progression. Tumour hypoxia can be detected by non-invasive and invasive techniques but the inter-relationships between these remains largely undefined. ¹⁸F-MISO and Cu-ATSM-PET, and BOLD-MRI are the lead contenders for human application based on their non-invasive nature, ease of use and robustness, measurement of hypoxia status, validity, ability to demonstrate heterogeneity and general availability, these techniques are the primary focus of this review. We discuss where developments are required for hypoxia imaging to become clinically useful and explore potential new uses for hypoxia imaging techniques including biological conformal radiotherapy.

Gray LH, Conger AD, Ebert M (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638–648PubMedCrossRef

Vaupel P (2004) The role of hypoxia-induced factors in tumor progression. Oncologist 9:10–17PubMedCrossRef

Brown JM (1999) The hypoxic cell: A target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 59:5863–5870PubMed

Vaupel P, Harrison L (2004) Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response. Oncologist 9:4–9PubMedCrossRef

Vaupel P, Kelleher DK, Hockel M (2001) Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28:29–35PubMedCrossRef

Kallinowski F, Zander R, Hoeckel M, Vaupel P (1990) Tumor tissue oxygenation as evaluated by computerized-pO2-histography. Int J Radiat Oncol Biol Phys 19:953–961PubMed

Vaupel P, Schlenger K, Knoop C, Hockel M (1991) Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 51:3316–3322PubMed

Brizel DM, Rosner GL, Harrelson J, Prosnitz LR, Dewhirst MW (1994) Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 30:635–642PubMed

Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509–4515PubMed

10.

Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77:18–24PubMedCrossRef

11.

Powis G, Kirkpatrick L (2004) Hypoxia inducible factor-1{alpha} as a cancer drug target. Mol Cancer Ther 3:647–654PubMed

12.

Belozerov VE, Van Meir EG (2005) Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 16:901–909PubMedCrossRef

13.

Hockel M, Vaupel P (2001) Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266–276PubMedCrossRef

14.

Caldwell JH, Revenaugh JR, Martin GV, Johnson PM, Rasey JS, Krohn KA (1995) Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. J Nucl Med 36:1633–1638PubMed

15.

Hall EJ, Giaccia AJ (2006) Oxygen effect and reoxygenation. In: Hall EJ, Giaccia AJ (eds) Radiobiology for the Radiologist. Lippincott Williams & Wilkins, Philadelphia, pp 85–105

16.

Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10:86–103PubMedCrossRef

17.

Bussink J, Kaanders JH, van der Kogel AJ (2003) Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 67:3–15PubMedCrossRef

18.

Williams KJ, Parker CA, Stratford IJ (2005) Exogenous and endogenous markers of tumour oxygenation status: definitive markers of tumour hypoxia? Adv Exp Med Biol 566:285–294PubMedCrossRef

19.

Rajendran JG, Krohn KA (2005) Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 43:169–187PubMedCrossRef

20.

Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, Grierson JR, Lindsley KL, Lewellen TK, Krohn KA et al (1995) Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography.Int J Radiat Oncol Biol Phys 33:391-398PubMed

21.

Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, Chin LK, Hofstrand PD, Grierson JR, Eary JF, Krohn KA (2003) [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 30:695–704PubMedCrossRef

22.

Ng P, Rajendran JG, Schwartz DL, Patterson LM, Scharnhorst J, Krohn KA (2003) Can [F-18] fluoromisonidazole PET imaging predict treatment response in head and neck cancer? J Nucl Med 44:128P

23.

Rajendran JG, Mankoff DA, O’Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA (2004) Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245–2252PubMedCrossRef

24.

Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ (2005) Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 32:1384–1391PubMedCrossRef

25.

Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A (1997) Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38:1155–1160PubMed

26.

Dearling JLD, Lewis JS, Mullen GED, Rae MT, Zweit J, Blower PJ (1998) Design of hypoxia-targeting radiopharmaceuticals: Selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 25:788–792PubMedCrossRef

27.

Dearling JLJ, Lewis JS, Welch MJ, McCarthy DW, Blower PJ (1998) Redox-active complexes for imaging hypoxic tissues: Structure-activity relationships in copper(II)bis(thiosemicarbazone) complexes. Chem Commun 22:2531–2533CrossRef

28.

Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ (1999) The evaluation of ⁶⁴Cu-diacetyl-bis(N ⁴-methylthiosemicarbazone)(⁶⁴Cu-ATSM) in vivo and in vitro in a hypoxic tumor model. J Nucl Med 40:177–183PubMed

29.

Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ (2001) Tumor uptake of copper-diacetyl-bis(N⁴-methylthiosemicarbazone): Effect of changes in tissue oxygenation. J Nucl Med 42:655–661PubMed

30.

Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ (2002) Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 7:249–259PubMedCrossRef

31.

Lewis JS, Herrero P, Sharp T, Engelbach JA, Fujibayashi Y, Laforest R, Kovacs A, Gropler RJ, Welch MJ (2002) Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N⁴-methylthiosemicarbazone). J Nucl Med 43:1557–1569PubMed

32.

Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GED (2002) Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem 45:1420–1431PubMedCrossRef

33.

Blower PJ, Lewis JS, Zweit J (1996) Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 23:957–980PubMedCrossRef

34.

Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, A SB (2003) In vivo assesment of tumor hypoxia in lung cancer with ⁶⁰Cu-ATSM. Eur J Nucl Med Mol Imaging 30:844–850PubMedCrossRef

35.

Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ (2003) Assessing tumor hypoxia in cervical cancer by positron emission tomography with ⁶⁰Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 55:1233–1238PubMed

36.

Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR (2001) Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 14:497–506PubMedCrossRef

37.

Robinson SP, Rijken PF, Howe FA, McSheehy PM, Van Der Sanden BP, Heerschap A, Stubbs M, Van Der Kogel AJ, Griffiths JR (2003) Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J Magn Reson Imaging 17:445–454PubMedCrossRef

38.

Kostourou V, Robinson SP, Whitley GS, Griffiths JR (2003) Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res 63:4960–4966PubMed

39.

Carnell DM, Taylor NJ, Smith RE, Hoskin PJ, Stirling JJ, d’Arcy J, Walker-Samuel S, Collins DJ, Leach MO, Padhani AR (2005) Evaluation of prostate gland hypoxia with quantified BOLD MRI: updated results from a correlated histological study. Miami, pp 270

40.

Taylor NJ, Baddeley H, Goodchild KA, Powell ME, Thoumine M, Culver LA, Stirling JJ, Saunders MI, Hoskin PJ, Phillips H, Padhani AR, Griffiths JR (2001) BOLD MRI of human tumor oxygenation during carbogen breathing. J Magn Reson Imaging 14:156–163PubMedCrossRef

41.

Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A (2002) Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging. Int J Radiat Oncol Biol Phys 53:1185–1191PubMedCrossRef

42.

Rodrigues LM, Howe FA, Griffiths JR, Robinson SP (2004) Tumor R2* is a prognostic indicator of acute radiotherapeutic response in rodent tumors. J Magn Reson Imaging 19:482–488PubMedCrossRef

43.

Neeman M (2002) Functional and molecular MR imaging of angiogenesis: Seeing the target, seeing it work. J Cell Biochem Suppl 39:11–17PubMedCrossRef

44.

Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, Koutcher JA (2000) Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47:551–560PubMedCrossRef

45.

Brahme A (2003) Biologically optimized 3-dimensional in vivo predictive assay-based radiation therapy using positron emission tomography-computerized tomography imaging. Acta Oncol 42:123–136PubMedCrossRef

46.

Bentzen SM (2005) Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6:112–117PubMedCrossRef

47.

Chao C, Bosch WR, Mutic S, Lewis JS, Dehdashti FD, Mintun MA, Demsey JF, Perez CA, Purdy JA, Welch MJ (2001) A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Biol Phys 49:1171–1182CrossRef

48.

Thorwarth D, Eschmann SM, Scheiderbauer J, Paulsen F, Alber M (2005) Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 5:152PubMedCrossRef

49.

Ljungkvist AS, Bussink J, Rijken PF, Kaanders JH, van der Kogel AJ, Denekamp J (2002) Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 54:215–228PubMed

50.

Collins DJ, Padhani AR (2004) Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag 23:65–83PubMedCrossRef

51.

Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, Krohn KA, Griffin TW (1992) Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 22:199–212PubMed

52.

Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, Krohn KA (1996) Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36:417–428PubMed

53.

Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla HJ, Bares R (2005) Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 46:253–260PubMed

54.

Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, Wester HJ, Beck R, McEwan AJ, Wiebe LI, Schwaiger M (2005) Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 46:106–113PubMed

55.

Evans SM, Kachur AV, Shiue CY, Hustinx R, Jenkins WT, Shive GG, Karp JS, Alavi A, Lord EM, Dolbier WR Jr, Koch CJ (2000) Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 41:327–336PubMed

Title: Imaging oxygenation of human tumours
Authors: Anwar R. Padhani
Kenneth A. Krohn
Jason S. Lewis
Markus Alber
Publication date: 01-04-2007
Publisher: Springer-Verlag
Published in: European Radiology / Issue 4/2007
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-006-0431-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Imaging oxygenation of human tumours

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2007

Acute retroperitoneal hemorrhage complicating a xanthogranulomatous pyelonephritis

Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal–pelvic phased-array coils

Characterization of focal liver lesions: comparative study of contrast-enhanced ultrasound versus spiral computed tomography

MR-compatible assistance system for punction in a high-field system: device and feasibility of transgluteal biopsies of the prostate gland

Assessment of lung disease in children with cystic fibrosis using hyperpolarized 3-Helium MRI: comparison with Shwachman score, Chrispin-Norman score and spirometry

A novel technique in selective venous sampling in the localization of parathyroid tumours utilizing a micro-wire and standardized catheter